Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Medtronic
Mallinckrodt
McKinsey
Colorcon

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR DIFLUCAN IN SODIUM CHLORIDE 0.9%


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Diflucan In Sodium Chloride 0.9%

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00075803 ↗ Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Completed Blood and Marrow Transplant Clinical Trials Network Phase 3 2003-11-01 The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.
NCT00075803 ↗ Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Completed National Cancer Institute (NCI) Phase 3 2003-11-01 The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.
NCT00075803 ↗ Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 2003-11-01 The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.
NCT00075803 ↗ Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Completed National Marrow Donor Program Phase 3 2003-11-01 The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.
NCT00075803 ↗ Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Completed Medical College of Wisconsin Phase 3 2003-11-01 The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.
NCT00166166 ↗ Endothelial Hyperpolarization in Humans Terminated National Heart, Lung, and Blood Institute (NHLBI) Phase 2 2002-07-01 The purpose of this study is to elucidate the role Endothelium-Derived Hyperpolarizing Factor (EDHF) plays in dilating blood vessels and whether it differs between healthy people and those with high cholesterol. A second purpose of the study is to determine the identity of EDHF.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Diflucan In Sodium Chloride 0.9%

Condition Name

Condition Name for Diflucan In Sodium Chloride 0.9%
Intervention Trials
Candidiasis 5
Fungal Infection 4
Healthy 3
Cryptococcal Meningitis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Diflucan In Sodium Chloride 0.9%
Intervention Trials
Candidiasis 14
Mycoses 9
Candidiasis, Vulvovaginal 5
Infections 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Diflucan In Sodium Chloride 0.9%

Trials by Country

Trials by Country for Diflucan In Sodium Chloride 0.9%
Location Trials
United States 157
Canada 14
Brazil 5
Italy 4
Spain 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Diflucan In Sodium Chloride 0.9%
Location Trials
California 9
Pennsylvania 8
North Carolina 8
Florida 8
Texas 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Diflucan In Sodium Chloride 0.9%

Clinical Trial Phase

Clinical Trial Phase for Diflucan In Sodium Chloride 0.9%
Clinical Trial Phase Trials
Phase 4 7
Phase 3 11
Phase 2 4
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Diflucan In Sodium Chloride 0.9%
Clinical Trial Phase Trials
Completed 27
Not yet recruiting 4
Unknown status 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Diflucan In Sodium Chloride 0.9%

Sponsor Name

Sponsor Name for Diflucan In Sodium Chloride 0.9%
Sponsor Trials
Pfizer 4
National Cancer Institute (NCI) 3
Astellas Pharma Inc 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Diflucan In Sodium Chloride 0.9%
Sponsor Trials
Other 45
Industry 25
NIH 10
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Merck
Express Scripts
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.